A new review in Current Cell Science brings together the science behind BRCA1, PSA, KRAS, and other biomarkers now used to detect cancer earlier and track how well the treatment is working. Cancer remains one of the leading causes of death worldwide, and part of what makes it so difficult to manage is its sheer diversity — more than 100 distinct types can arise, depending on which tissue or organ is affected. A new review, published ahead-of-print in Current Cell Science, takes stock of one of the most important tools researchers and clinicians now rely on to make sense of this complexity: cancer biomarkers.

New bioinformatics study screens three diabetes-linked genes and builds PCR primers that could support low-cost genetic risk testing, particularly in resource-limited settings. Diabetes is one of the fastest-growing health concerns worldwide, and a large share of that burden falls on developing countries where early screening tools are often too expensive or too complex for routine use. A new study, published ahead of print in Current Science, Engineering and Technology, tackles this problem from the perspective of genetics, i.e., by designing and computationally testing molecular tools that could one day help identify people at higher genetic risk of type 2 diabetes before the disease develops.New bioinformatics study screens three diabetes-linked genes and builds PCR primers that could support low-cost genetic risk testing, particularly in resource-limited settings. Diabetes is one of the fastest-growing health concerns worldwide, and a large share of that burden falls on developing countries where early screening tools are often too expensive or too complex for routine use. A new study, published ahead of print in Current Science, Engineering and Technology, tackles this problem from the perspective of genetics, i.e., by designing and computationally testing molecular tools that could one day help identify people at higher genetic risk of type 2 diabetes before the disease develops.

A global study found that Singapore ranked first in the world in 2023 for both life expectancy, at 85.4 years, and healthy life expectancy, at 74.1 years. However, the gap between the two widened to 11.2 years, up from 8.9 years in 1990, with women living longer than men but spending more years in poor health.

In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that the anticipated price reductions of up to 70% will dramatically increase both the cost-effectiveness and health system affordability of therapy options for patients with type 2 diabetes and high cardiorenal risk. The new study in the Canadian Journal of Cardiology, published by Elsevier, provides key evidence regarding reimbursement and formulary decisions.